Compare Gilead Sciences, Inc. (GILD) vs New York Times Co (NYT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs New York Times Co — how do they compare? Gilead Sciences, Inc. trades at $135.66 (market cap $168.35B), while New York Times Co trades at $63.73 (market cap $10.28B). The key difference: Gilead Sciences, Inc. is far larger — about 16.4× New York Times Co's market cap, and Gilead Sciences, Inc. pays the higher dividend (2.42%). Which is the better fit depends on your goals.
| GILD | NYT | |
|---|---|---|
Market Cap | $168.35B | $10.28B |
Sector | Health | Media |
52-Week High | $155.80 | $85.86 |
52-Week Low | $110.56 | $54.66 |
Enterprise Value | $191.42B | $9.67B |
Dividend Yield | 2.42% | 1.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $135.78, up 2.04% on the day, with a bullish technical signal and strong support at $134. Recent Q2 2026 earnings beat revenue estimates despite a net loss, driven by 10% base business growth from HIV drugs like Biktarvy. The company raised its full-year sales outlook, but faces a negative net income margin of -10.64% and elevated debt levels.
The outlook is mixed: robust HIV franchise growth and a 67% analyst buy rating support upside to the $151.22 consensus target, but acquisition costs, patent cliff risks, and volatile cash flows pose challenges. Investment appeal hinges on pipeline execution offsetting margin pressure.
The New York Times (NYT) trades at $63.93, down 1.34% amid bearish technical signals despite strong Q2 2026 earnings beats. Revenue growth continues with 2025 revenue reaching $2.82B and net income margin expanding to 12.17%. The stock faces technical pressure with RSI at oversold levels near key support at $62-63, while analyst consensus remains cautious with 65% hold ratings.
NYT demonstrates solid fundamental growth with expanding profitability and digital subscription strength, but faces near-term headwinds from slowing subscriber growth and technical weakness. The $77.50 consensus price target suggests 21% upside potential, though execution risks and competitive pressures warrant monitoring for current investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About New York Times Co
New York Times Co is an American media company known for publishing its flagship newspaper, The New York Times. The company also operates the International New York Times newspaper, as well as digital properties such as nytimes and various smartphone applications. Circulation of The New York Times is the source of revenue for the company, followed by print and digital advertising and its paid digital-only subscription to The New York Times. The company has a daily print circulation of over 500,000 and 1,000,000 on Sundays. The source of growth for The New York Times is its digital subscription service, which has over 1,000,000 paid users.
Read more on NYT →
